Pieter van der Meer
Oprichter bij Gilde Healthcare Partners BV
Oorsprong van het eerstegraads netwerk van Pieter van der Meer
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge.
22
| Subsidiary | Investment Managers | 22 |
Subsidiary | Pharmaceuticals: Other | 10 | |
LUMICKS Technologies Bv
9
| Subsidiary | 9 | |
Lumicks BV
Lumicks BV Miscellaneous Commercial ServicesCommercial Services Lumicks BV is a Dutch life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis. The company is based in Amsterdam, NL, and has subsidiaries in the Netherlands and the United States. The company's tools allow researchers to analyze complex biological processes in real-time by applying and measuring forces around biological interactions. Lumicks' C-Trap® optical tweezers and fluorescence & label-free microscopy, and Z-Movi® cell avidity analyzer are used to measure and select immune cells based on their real-time interactions with target cells. Lumicks was founded in 2014 by Olivier Heyning and Andrea Candelli, with Olivier Heyning serving as the CEO since then.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Gilde Investment Management BV
Gilde Investment Management BV Investment ManagersFinance Gilde Investment Management BV is an Independent Private Equity firm founded in 1982. Gilde Investment Management BV is headquartered in Utrecht.
3
| Private Company | Investment Managers | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Pieter van der Meer via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
Micreos BV
Micreos BV Pharmaceuticals: GenericHealth Technology Micreos BV develops phage-based products against specific dangerous bacteria. It offers human health, food safety, agriculture and animal health products. The company was founded by Mark Offerhaus and is headquartered in Wageningen, the Netherlands. | Pharmaceuticals: Generic | Chairman | |
SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member | |
BTG | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Chairman | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member | |
First Cambridge Gateway LP | Investment Managers | Chief Investment Officer | |
MVM Partners LLP
MVM Partners LLP Investment ManagersFinance MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom. | Investment Managers | Private Equity Investor | |
OC&C | Consultant / Advisor | ||
University of Cambridge | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Director/Board Member | |
INSEAD | College/University | Masters Business Admin Masters Business Admin Graduate Degree | |
ELECTRICAL GEODESICS INC | Medical Specialties | Director of Finance/CFO Director/Board Member | |
Erasmus University Rotterdam | College/University | Graduate Degree Graduate Degree | |
University of Leiden | College/University | Undergraduate Degree Doctorate Degree | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Gilde Healthcare Holding BV
Gilde Healthcare Holding BV Financial ConglomeratesFinance Gilde Healthcare Holding BV is an investment holding Dutch company. The private company is based in Utrecht, NL. and has subsidiaries in Australia, Netherlands, United States and Germany. The CEOs of the company are Edwin William de Graaf, Marc Olivier Perret. | Financial Conglomerates | Chief Executive Officer Chief Executive Officer | |
BiognoSYS AG
BiognoSYS AG Packaged SoftwareTechnology Services BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland. | Packaged Software | Chairman | |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Pharmaceuticals: Major | Chairman | |
Athyrium Capital Management LP
Athyrium Capital Management LP Investment ManagersFinance Athyrium Capital Management LP (Athyrium) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Jeffrey A. Ferrell in 2008 as Athyrium Capital Management LLC and converted from a Delaware limited liability company to a Delaware limited partnership in 2015. Athyrium provides advisory services on a discretionary basis to its clients, which may include specific tailored vehicles and pooled investment vehicles intended for sophisticated investors and institutional investors. | Investment Managers | Consultant / Advisor | |
ARCH BIOPARTNERS INC. | Pharmaceuticals: Major | Director/Board Member | |
INHIBIKASE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
CIRCIO HOLDING ASA | Biotechnology | Chairman | |
Chiroscience Ltd. | Corporate Officer/Principal Corporate Officer/Principal | ||
SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
ADVANZ PHARMA CORP. LIMITED | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Other | Chairman | |
Cell Therapy Catapult Ltd.
Cell Therapy Catapult Ltd. BiotechnologyHealth Technology Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Chairman | |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Chief Executive Officer | |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman | |
Oviva AG
Oviva AG Miscellaneous Commercial ServicesCommercial Services Oviva AG provides online medical nutritional counseling services. Its dietitians provide treatment and care services for various medical problems in adult and pediatric populations, such as obesity, type 1 and type 2 diabetes, high blood sugar, heart disease and stroke, digestive diseases, and allergy and intolerances directly in GP and specialist clinics, as well as remotely. The company was founded in 1999 and is headquartered in Schwyz, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Essential Pharmaceuticals LLC
Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Intas Pharmaceuticals Ltd., Essential Pharmaceuticals LLC is a company that manufactures and markets pharmaceutical products. The company is based in Durham, NC. The company was founded in 2006. Emma Jane Johnson has been the CEO of the company since 2023. Essential Pharmaceuticals was acquired by Accord Healthcare, Inc. on July 26, 2017. | Pharmaceuticals: Major | Chairman | |
Owkin, Inc.
Owkin, Inc. Packaged SoftwareTechnology Services Owkin, Inc. operates as an artificial intelligence company. It develops software which allow prediction modeling and population comparison services. The firm's products include OWKIN Socrates and OWKIN Services. The company was founded by Thomas Clozel and Gilles Wainrib in 2016 and is headquartered in Albany, NY. | Packaged Software | Director/Board Member | |
Essential Pharmaceuticals Ltd.
Essential Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Essential Pharmaceuticals Ltd. manufactures pharmaceutical products. The company was founded on November 24, 2010 and is headquartered in Egham, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Gateway Fund Co. Pte Ltd. | Corporate Officer/Principal | ||
Impresa Management LLC (United Kingdom) | Investment Managers | Private Equity Investor | |
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member | |
Ciwit BV
Ciwit BV Internet Software/ServicesTechnology Services Ciwit BV provides electronic data capture platform for medical research. The company was founded by Derk Arts in 2011 and is headquartered in Amsterdam, the Netherlands. | Internet Software/Services | Director/Board Member | |
ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Gyrus Capital SA | Investment Managers | Private Equity Investor | |
Arvelle Therapeutics International GmbH
Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
F-Prime UK Ltd.
F-Prime UK Ltd. Miscellaneous Commercial ServicesCommercial Services F-Prime UK Ltd. was founded in 2007 and provides strategy development, market research, investment advisory, and administration support services. The private company is based in London, UK. | Miscellaneous Commercial Services | Director/Board Member | |
AMRYT PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
Synexa Life Sciences BV
Synexa Life Sciences BV BiotechnologyHealth Technology Synexa Life Sciences BV is a Dutch company that specializes in Biomarker and Bioanalysis Research Services. The company is based in Leiden, Netherlands. The company has expertise in designing and delivering biomarker strategies for biopharma clients. and has subsidiaries in Finland. The company was founded in 2003 by Justin Devine, Patrick Bouic, Paul O'Riordan. The CEO is Emile Lens. | Biotechnology | Director/Board Member Director/Board Member | |
Tenpoint Therapeutics Ltd.
Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | Biotechnology | Director/Board Member | |
F2g Inc. | Director/Board Member |
Statistieken
Internationaal
Verenigd Koninkrijk | 22 |
Verenigde Staten | 11 |
Nederland | 7 |
Zwitserland | 7 |
Frankrijk | 2 |
Sectoraal
Health Technology | 30 |
Finance | 8 |
Consumer Services | 5 |
Commercial Services | 4 |
Technology Services | 4 |
Operationeel
Director/Board Member | 194 |
Chairman | 53 |
Corporate Officer/Principal | 47 |
Private Equity Investor | 37 |
Independent Dir/Board Member | 36 |
Sterkste connecties
Insiders | |
---|---|
John Brown | 36 |
Ed Borkowski | 32 |
Carl Johan Kördel | 31 |
Patrick Volkert Vink | 30 |
Erik Walldén | 22 |
Steven Powell | 22 |
Donald Kania | 21 |
Ian Fletcher Kent | 20 |
Alexander Pasteur | 19 |
Christine Soden | 18 |
Edwin de Graaf | 14 |
Julian Gilbert | 14 |
Janke Dittmer | 13 |
Gary Gemignani | 13 |
Arthur Franken | 11 |
- Beurs
- Insiders
- Pieter van der Meer
- Bedrijfsconnecties